Viking Therapeutics (NASDAQ: VKTX)
Viking Therapeutics Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Viking Therapeutics Company Info
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.
News & Analysis
1 Stock Down 34% This Year to Buy and Hold
What Companies Does Johnson & Johnson Own?
Could Viking Therapeutics Become the Next Eli Lilly?
Why Viking Therapeutics Stock Bumped 3% Higher Today
2 Monster Stocks in the Making to Buy Now and Hold for 10 Years
Why Viking Therapeutics Stock Surged Nearly 20% Higher in April
Why Viking Therapeutics Stock Was Victorious This Week
Where Will Viking Therapeutics Be in 3 Years?
Viking's leading drug candidate could be a blockbuster in the weight loss market, which experts believe could grow to $150 billion over the coming years.
Valuation
Earnings Transcripts
Viking Therapeutics (VKTX) Q2 2022 Earnings Call Transcript
VKTX earnings call for the period ending June 30, 2022.
Viking Therapeutics (VKTX) Q1 2022 Earnings Call Transcript
VKTX earnings call for the period ending March 31, 2022.
Viking Therapeutics (VKTX) Q4 2021 Earnings Call Transcript
VKTX earnings call for the period ending December 31, 2021.
Viking Therapeutics (VKTX) Q3 2021 Earnings Call Transcript
VKTX earnings call for the period ending September 30, 2021.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.